We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G 
Introduction
In infant leukemias, the translocations involved in chromosome 11q23 are the most common chromosomal abnormalities [1] [2] [3] and rearrangements of the MLL gene located on breakpoints at 11q23 have been demonstrated. [4] [5] [6] Based on ultrastructural, immunological, and molecular characteristics of the blasts, it has been suggested that acute lymphoblastic leukemia (ALL) with 11q23 translocations usually show CD10-negative immature B-lineage or mixed-lineage phenotype, and arise from a multipotential stem cell. 1, 3, [7] [8] [9] [10] Of clinical importance, these leukemias are usually refractory to the standardized treatment regimens, and the most intensified chemotherapy and/or hematopoietic stem cell transplantation is required to improve their prognosis. 3, [7] [8] [9] [10] [11] Accordingly, in patients with these leukemias, granulocyte colony-stimulating factor (G-CSF) is commonly used for severe neutropenia following multidisciplinary chemotherapy and/or transplantation to help recovery of granulopoiesis. 12, 13 Although G-CSF has been initially considered as a factor that acts specifically on cells committed to the neutrophilic granulocyte lineage, 13 it is now known that G-CSF supports the survival, proliferation, and differentiation of multipotential hematopoietic stem cells [14] [15] [16] [17] [18] [19] as well as granulocytic precursors. In addition, we recently showed that normal B-precursor cells increased in bone marrow after chemotherapy, express G-CSF receptor (G-CSFR), suggesting a possible participation of the G-CSF/G-CSFR interaction in the process of B cell ontogeny. 20 In this paper, we report a boy with t(11q23)-ALL whose Correspondence: K Sugita, The Department of Pediatrics, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakakoma-gun, Yamanashi 409-38, Japan; Fax: 81 552 73 6745 Received 31 August 1997; accepted 18 November 1997 blasts markedly increased in peripheral blood just after intravenous G-CSF administration. The in vitro study showed that the leukemic cells separated from this patient expressed G-CSFR and their proliferation was stimulated with G-CSF. In order to clarify whether this observation can be generalized or not, we examined the G-CSFR expression on eight leukemic cell lines with 11q23 translocations and their response to G-CSF. We found that all cell lines examined expressed G-CSFR and most of them were stimulated in response to G-CSF, suggesting a possible participation of the G-CSF/G-CSFR interaction in the process of growth regulation of leukemic cells with 11q23 translocations.
Case report
A 16-month-old boy without previous medical history was admitted for fever and anemia in July 1992. Physical examination revealed moderate hepatosplenomegaly. The peripheral blood count showed the following: leukocyte, 33 900/l (64% blast cells); hemoglobin, 4.1 g/dl; and platelets, 169 × 10 3 /l. The bone marrow aspirate contained 90% lymphoblastoid cells (L2 in FAB classification) which were negative for peroxidase and ␣-naphthyl butyrate esterase (␣-NBE). The blasts were positive for HLA-DR, but negative for B cell-related (CD10, 19, 20 and 22), T cell-related (CD1, 2, 3, 4, 5, 7 and 8) and myeloid-related (CD11b, 13, 14, 33, 36, 41, 42 and glycophorin A) antigens, and thus he was diagnosed to have ALL (undifferentiated type). Cytogenetic study was carried out, but failed at this time. The combined chemotherapy for highrisk ALL according to the TCCSG regimen 21 was started, and 1 month later complete remission was achieved. At 4 months from the onset, G-CSF (5 g/kg/day) was administered intravenously for severe neutropenia after consolidation chemotherapy. After 3 days' use of G-CSF, leukemic blasts were detected in peripheral blood (2600/l) with the concomitant increase in normal granulocytes as shown in Figure 1 . Leukemic blasts disappeared from peripheral blood after stopping G-CSF. However, 3 days after readministration of G-CSF, which was given for recurred severe neutropenia with high fever, the blasts increased again to 6800/l in peripheral blood and the relapse of the disease was confirmed by bone marrow aspiration. The blasts at relapse remained negative for peroxidase and ␣NBE, but showed early pre B-cell phenotype (HLA-DR
. Cytogenetic study on BM cells demonstrated that three out of 20 cells analyzed have t(11;15)(q23;q14-15), which is an uncommon chromosomal abnormality in acute non-lymphoblastic leukemia (ANLL) frequently expressing lymphoid antigens. 22, 23 The rearrangement of the MLL gene was also demonstrated. Although the second remission was achieved by a combined chemotherapy consisting of etoposide, cytosine arabinoside and mitoxantrone, he died of sepsis in spite of all efforts in June 1993. The total clinical course lasted 12 months.
Figure 1
Clinical course of the presented case. At 4 months from the onset, G-CSF (5 g/kg/day) was administered intravenously for severe neutropenia after consolidation chemotherapy. After 3 days' use of G-CSF, leukemic blasts increased in peripheral blood, but disappeared after stopping G-CSF. However, 3 days after readministration of G-CSF, the blasts increased again and the relapse of the disease was confirmed by bone marrow aspiration. The second remission was achieved by a combined chemotherapy consisting of etoposide (VP-16), cytosine-arabinoside (Ara-C), and mitoxantrone (MIT).
Materials and methods

Cells
Mononuclear cells were separated by Ficoll-Hypaque density centrifugation from peripheral blood of the patient presented in this paper, one with acute myelogenous leukemia (AML) (FAB classification; M1, positive control), and nine children with common (c)ALL (controls). All samples contained Ͼ90% blasts, and viability of the cells was always Ͼ95%. Normal granulocytes were obtained as pellets from peripheral blood of healthy volunteers by dextran sedimentation followed by density centrifugation.
Cell lines
Eight leukemic cell lines with 11q23 translocations were established from infantile acute leukemic patients in our laboratory, 24 and were used in this study. Their characteristics such as karyotype, cytochemistry, and surface antigens were summarized in Table 1 . All cell lines were negative for peroxidase. KOCL-33, -44, -48, and -50 have a 11;19 translocation, and KOCL-45, -51, -58, and -69 have a 4;11 translocation. KOCL-48 which is ␣-NBE-positive and expresses myelomonocytoid antigens was classified into 'monocytoid' type. KOCL-45, -51, -58, and -69 which are ␣-NBE-negative and express both myeloid and immature B-lymphoid antigens were classified into 'biphenotypic' type. KOCL-33, -44, and -50, which are ␣-NBE-negative and express immature B-lymphoid antigens, were classified into 'lymphoid' type. As controls, KOPT-5, a CD3-positive mature T cell line, and YAM-B1, an EpsteinBarr virus-transformed B cell line, were also used. These cell lines are maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) in a fully humidified atmosphere of 5% CO 2 at 37°C. Before experiments, cell lines were washed twice with RPMI 1640 medium.
Immunophenotype
Immunophenotypic analysis of patient's samples and cell lines was performed by indirect immunorosette method as previously reported. 25, 26 Following mAbs shown in parentheses were used: CD1 (T6), CD2 (T11), CD3 (Leu4, T3), CD4 (T4), CD5 (T1, SL-1), CD7 (Tp40), CD8 (T8), CD25 (IL-2R1), CD10 (J5), CD19 (B4), CD20 (B1), CD21 (B2), CD22 (Leu14), CD11b (Leu15), CD13 (My7), CD14 (My4), CD33 (My9), CD34 (HPCA-2), CD36 (OKM5), CD41 (TP80), CD42b (AN51), glycophorin A (KOR-E6), CD56 (NKH-1), HLA-DR (I2). Leu4, Leu14, Leu15, and HPCA-2 were purchased from Beckton Dickinson (San Jose, CA, USA) and AN51 was from Dako (Copenhagen, Denmark). TP80 was a kind gift of Dr Ryuzo Ueda, Laboratory of Chemotherapy, Aichi Cancer Research Institute, Nagoya, Japan. KOR-E6 was produced in our laboratory. 27 Other mAbs were purchased from Coulter Immunology (Hialeah, FL, USA).
G-CSFR assay
Recombinant human G-CSF (rhG-CSF) was kindly provided by Chugai Pharmaceutical Co (Tokyo, Japan). To detect the G-CSFR, biotinylated G-CSF was first produced as reported previously. 20, 28 In brief, 0.5 ml of G-CSF solution (500 g/ml) dialyzed against sodium bicarbonate (0.2 m, pH 8.4) was mixed with 25 l of biotinyl N-hydroxysuccinimide ester (Sigma Chemical Co, St Louis, MO, USA) in dimethyl sulfoxide (10 mg/ml), and incubated at room temperature for 4 h and at 4°C overnight. The G-CSF solution was dialyzed against PBS twice. The final concentration of biotinylated G-CSF was 200 ng/l.
One million mononuclear cells or leukemic cells were incubated with 2 l of biotinylated G-CSF. As a negative control, 100-fold excess of unlabeled G-CSF were also added. After incubation for 60 min at 4°C, the cells were washed twice with ice-cold PBS in the presence of 0.05% sodium azide and incubated with streptavidin-phycoerythrin (Biomeda, CA, USA) for 30 min at 4°C. These cells were washed and analyzed using a flow cytometry (EPICS Profile Analyzer; Coulter).
Thymidine incorporation assay
Mononuclear cells separated from patients were cultured in 200 l of RPMI 1640 medium supplemented with 10% FCS in flat-bottomed 96-well plates (Costar, Cambridge, MA, USA) at 1 × 10 5 cells/well. rhG-CSF was added to wells in triplicate at a final concentration of 0, 1, 10 and 100 ng/ml. In leukemic cell lines, the cells were cultured at various densities from 1 × 10 4 to 1 × 10 5 cells/well, and final concentrations of rhG-CSF were 0, 0.1, 1, 10 and 100 ng/ml. The plates were incubated at 37°C, 5% CO 2 in a humidified atmosphere for 48 h, pulsed for 6 h with 3 H-thymidine (1 Ci/well), and harvested on to glass-fiber filters using a cell harvester. Radioactivity incorporated into DNA was measured by liquid scintillation counting. Statistical comparison was performed by a paired ttest, and P value Ͻ0.05 was considered as significant. A stimulation index (SI) was also calculated as the ratio of the maximal 3 H-thymidine (c.p.m.) incorporated in the presence of rhG-CSF to the 3 H-thymidine (c.p.m.) incorporated in the absence of rhG-CSF.
Changes in morphology and surface antigens expression by G-CSF under suspension culture Leukemic cell lines were cultured in RPMI-1640 supplemented with 10% FCS in the absence or presence of rhG-CSF (10 ng/ml). Cultures were started in flat-bottomed six-well plates (4 × 10 6 cells/8 ml). The morphology of the cells was observed every 3 days (up to day 12) on cytospin smears after Wright-Giemsa staining. Surface antigens (CD19, CD13, CD14, CD33) expression was also examined every 3 days (up to day 12) by direct immunofluorescence using a flow cytometer.
Results
The G-CSFR expression on the patient's leukemic cells and their proliferative response to G-CSF in vitro First, we examined the G-CSFR expression on the blasts of this case using biotinylated G-CSF. As shown in Figure 2c , G-CSFR was detected on approximately 10% of the blasts. To estimate whether the leukemic blasts of the patient are actually stimulated in response to G-CSF in vitro, we next examined the incorporation of 3 H-thymidine by the blasts at relapse in the absence or presence of G-CSF. As shown in Table 2 , G-CSF induced marked increase in 3 H-thymidine incorporation at any concentrations of G-CSF. The maximal 3 H-thymidine incorporation (SI = 4.9) was observed at a concentration of 10 ng/ml, which corresponds to the plateau concentration of G-CSF in peripheral blood when G-CSF is clinically administered. 29 Although the in vitro response to G-CSF of the blasts from this case was not as high as that of the blasts from AML (M1) patient (SI = 16.7) analyzed as a positive control, the SI of this case was significantly higher (P Ͻ 0.0001, t-test) than that of cALL patients (1.00 ± 0.23; mean ± s.d., n = 9).
These results suggested that some of the blasts of this patient expressed G-CSFR and their proliferation was actually stimulated in response to a clinically used concentration of G-CSF.
Expression of G-CSFR on leukemic cell lines with 11q23 translocations
To examine whether the leukemic cells in this case are exceptional or consistent with leukemic cells with 11q23 translocations in terms of the G-CSFR expression, we used eight leukemic cell lines with 11q23 translocations (Table 1) established from infant leukemias in our laboratory. 24 As shown in Table 3 , all of the eight leukemic cell lines expressed G-CSFR (20-98%). Flow cytometric histograms of eight leukemic cell lines and KOPT-5 as a negative control are shown in Figure 3 . The G-CSFR positive cells were 20% on KOCL-48 ('monocytoid' type), 36% to 88% (mean, 57%) on KOCL-45, -51, -58, -69 ('biphenotypic' type), and 50% to 98% (mean, 67%) on KOCL-33, -44, -50 ('lymphoid' type). Among three types, 'lymphoid' type leukemic cell lines equally or rather strongly expressed G-CSFR compared with 'monocytoid' or 'biphenotypic' type cell lines, although not statistically significant by Mann-Whitney test.
Proliferative responses of leukemic cell lines with 11q23 translocations to G-CSF
We next examined proliferative response to G-CSF using eight leukemic cell lines with 11q23 translocations. The maximal uptake of 3 H-thymidine with G-CSF and its concentration were summarized in Table 3 . Proliferative responses to different concentrations of G-CSF were shown in Figure 4 . G-CSF stimulated proliferation most potently in a 'monocytoid' type cell line (SI = 13.40), moderately in 'biphenotypic' type cell lines (SI = 1.14 to 4.08, mean 2.75), and most modestly in 'lymphoid' type cell lines (SI = 1.27 to 1.89, mean 1.45). In summary, proliferation of seven out of eight leukemic cell lines was significantly (P Ͻ 0.05) enhanced in response to G-CSF and five of their stimulation indices were Ͼ1.5 (1.89-13.4), although optimal concentrations of G-CSF for their maximal proliferative responses varied among leukemic cell lines.
Effect of G-CSF on morphology and surface antigens expression in leukemic cell lines with 11q23 translocations under suspension culture
We tested changes in morphology and surface antigens (CD19, CD13, CD14 and CD33) expression under suspension culture with G-CSF in these eight cell lines, and detected no changes at least up to day 12 (data not shown).
Discussion
It has been well known that AML cells frequently express G-CSFR [28] [29] [30] [31] [32] [33] [34] and their proliferation are often stimulated with G-CSF. 30, 32, 33 In contrast, Mirro et al 35 reported that ALL cells rarely respond to cytokines including G-CSF. In their report, 25 of 52 samples from childhood AML responded to G-CSF, whereas only one of 81 samples from childhood ALL including five infant leukemias was responsive to G-CSF. Thus, G- CSF has been widely used in ALL patients to promote recovery of granulocyte precursors following an intensified chemotherapy.
However, the lymphoblasts with 11q23 translocation presented in this paper expanded in peripheral blood in response to the administration of G-CSF, and the in vitro study demonstrated that the blasts expressed G-CSFR and responded to G-CSF. This clinical experience led us to the hypothesis that leukemic cells with 11q23 translocations frequently express G-CSFR and their proliferation might be stimulated with G-CSF. In order to address this, we examined the expression of G-CSFR using biotinylated G-CSF and the stimulatory effect of G-CSF on eight leukemic cell lines with 11q23 translocations using thymidine incorporation assay. We identified G-CSFR on all of these cell lines and demonstrated G-CSF-induced stimulation of DNA synthesis in seven out of eight leukemic cell lines. Of interest, the stimulatory effect by G-CSF did not correlate to the densities of G-CSFR expressed on cells. For instance, the patient's leukemic cells and cell line KOCL-48 were markedly stimulated with G-CSF, but expressed G-CSFR at lower levels, while cell line KOCL-58 was not stimulated with G-CSF, but expressed G-CSFR at C, cytoplasmic -chain; ␣-NB, ␣-naphthyl butyrate esterase; −, Ͻ5%; ±, 5-9%; +, 10-50%; ++, Ͼ50%. higher levels. These results suggest that the sensitivity of cells to G-CSF is dependent on the presence or absence of intracellular systems (intact cytoplasmic region of G-CSFR, JAK-STAT pathway etc) which are capable of transmitting the signals from G-CSFR to their nucleoli, 18, 19, 36 but not on the density of G-CSFR. In AML, several reports have indicated the irrelevance of the density of G-CSFR to the sensitivity of cells to G-CSF, 28, 30, 31, 33 which are consistent with our result. G-CSF was initially considered as a factor that acts specifically on cells committed to the neutrophilic granulocyte lineage. 13 Recent observations, however, have indicated that the targets of G-CSF may include multipotential hematopoietic progenitors. [14] [15] [16] [17] [18] [19] 21 Acute leukemia with 11q23 translocations is also considered to arise from such a multipotential stem cell, 1,3-11 which might support the result shown in this paper that leukemic cells with 11q23 translocations are responsive to G-CSF. Kita et al 37 showed that mRNA of G-CSFR was expressed in the CD7-positive non-T ALL and some of these leukemic blasts were stimulated by G-CSF in vitro and in vivo. We also recently found that Philadelphia chromosome (Ph1)-positive leukemia cells frequently expressed G-CSFR and their proliferation was stimulated by exogenously added or endogenously secreted G-CSF (manuscript in preparation). In addition, two of three biphenotypic leukemic cell lines without Ph1 and 11q23 translocations were also responsive to G-CSF (data not shown). These leukemias, including CD7-and Ph1-positive leukemias, are also considered to arise from the stem cell levels. 37, 38 According to these observations, leukemic cells just branching off from a downstream of multipotential stem cells might express G-CSFR and have the potential to respond to G-CSF. Hirayama et al 39 showed that G-CSF can support the proliferation of normal murine B-lineage precursors in the presence of steel factor, supporting this notion observed in leukemic cells.
Clinically, use of G-CSF might not be recommended after chemotherapy in ALL with 11q23 translocations because there is the possibility that G-CSF may facilitate relapse of the disease. However, to conclude this, long-term observation and Table 3 .
Figure 4
Proliferative response of leukemic cell lines with 11q23 translocations to different concentrations of G-CSF. Proliferative responses of eight leukemic cell lines with 11q23 translocations and a T cell line (KOPT-5, negative control) to different concentrations of G-CSF were examined using 3 H-thymidine incorporation assay as described in Materials and methods. The results were shown as the stimulation index at each of the G-CSF concentrations. multicentric analysis will be required because G-CSF may improve event-free survival by preventing severe infections and/or shortening the interval between programs of chemotherapy, 40, 41 as reported in AML by Ohno et al. 12 On the contrary, it is highly possible that use of G-CSF during chemotherapy enhances the cytotoxic effects of anti-leukemic agents by inducing leukemic cells with 11q23 translocations from G 0 -phase into the chemotherapy-sensitive G 1 -and S-phases as reported in GM-CSF. 42 In this regard, it may be very useful to use G-CSF, together with a preconditioning regimen, in autologous or allogeneic bone marrow transplantation for leukemia with 11q23 translocations.
